SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the Dual mTOR Kinase Inhibitor Vistusertib (AZD2014) for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2018
At a glance
- Drugs Selumetinib (Primary) ; Vistusertib (Primary)
- Indications Nerve sheath neoplasms; Neurofibromatoses
- Focus Therapeutic Use
- 11 Jun 2018 Planned initiation date changed from 1 May 2018 to 1 Jul 2018.
- 10 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 May 2018.
- 16 Feb 2018 New trial record